Asklepios BioPharmaceutical

Bayer and Acuitas Therapeutics Join Forces for Targeted Gene Editing Delivery

Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its…

11 months ago

Bayer: Viralgen Vector Core Licensed for Large-Scale recombinant adeno-associated virus (rAAV) Gene Therapy Production

(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the…

1 year ago

Bayer: Viralgen Vector Core con licencia para la producción de terapia génica de virus adenoasociados recombinantes (rAAV) a gran escala

(COMUNICADO DE PRENSA) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), una empresa global con competencias básicas en…

1 year ago